We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Track real-time Director Deals activity on the London Stock Exchange (LSE)
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 9.775 | 17,000 | 08:00:15 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 9.30 | 10.25 | 9.775 | 9.775 | 9.775 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | -5.86M | -0.0057 | -17.14 | 101.35M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 08:49:48 | O | 17,000 | 9.775 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 21/5/2025 | 07:00 | UK RNS | Scancell Holdings Plc Director Dealing |
| 14/4/2025 | 14:02 | ALNC |  Scancell partners with NHS to fast-track melanoma vaccine trial |
| 14/4/2025 | 07:00 | UK RNS | Scancell Holdings Plc Partnership with NHS Cancer Vaccine Launch Pad |
| 01/4/2025 | 07:00 | UK RNS | Scancell Holdings Plc Scancell to present at 2025 AACR Annual Meeting |
| 20/2/2025 | 07:00 | UK RNS | Scancell Holdings Plc Issue of share options |
| 17/2/2025 | 07:00 | UK RNS | Scancell Holdings Plc Scancell presenting at AACR IO conference |
| 30/1/2025 | 19:54 | ALNC | IN BRIEF: Scancell hurt by revaluation of derivative liability loss |
| 30/1/2025 | 07:00 | UK RNS | Scancell Holdings Plc Interim Results |
| 23/1/2025 | 07:00 | UK RNS | Scancell Holdings Plc Notice of Interim Results |
| 09/1/2025 | 11:43 | ALNC | Scancell encouraged by early results in cancer vaccine trial |
Scancell (SCLP) Share Charts1 Year Scancell Chart |
|
1 Month Scancell Chart |
Intraday Scancell Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 19/6/2025 | 10:15 | Scancell - Pot of Gold or POS? | 20,299 |
| 06/6/2025 | 14:49 | Scancell investors thread (litter free) | 609 |
| 20/1/2025 | 22:51 | Using immunology to fight cancer. | 57,676 |
| 19/1/2025 | 17:54 | Market cap to surpass Ј1 BILLION in the next few years | 19 |
| 14/6/2024 | 12:23 | Scancell for investors (inanaco free thread) | 237 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 07:49:49 | 9.78 | 17,000 | 1,661.75 | O |
| 2025-06-18 13:40:57 | 9.78 | 18 | 1.76 | O |
| 2025-06-18 12:43:48 | 9.40 | 686 | 64.45 | O |
| Top Posts |
|---|
Posted at 19/6/2025 09:20 by Scancell Daily Update Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 9.78p.Scancell currently has 1,036,781,403 shares in issue. The market capitalisation of Scancell is £101,293,543. Scancell has a price to earnings ratio (PE ratio) of -17.14. This morning SCLP shares opened at 9.78p |
Posted at 13/6/2025 09:47 by bermudashorts marcus - yes, can't remember the terms of the GSK deal but assume there may also be future milestones and royalties too? Makes sense for both parties for a variety of reasons. This and the patent litigation have to be taken into account if you're looking at the valuation of the deal of course.sci102 - apologise for what? For highlighting both the investment case and the risk? For being honest about reducing my holding because of extended timelines? For challenging the no risk mantra over and over? You seem to have a pretty low opinion of the intelligence level of other posters if you think they aren't able to read all contributions on these boards across the whole spectrum, do their own research and make their own investment decisions. Most here will have seen several opportunities to take profit and de-risk and many have done just that. If SCLP turns south, I will be very sorry for anyone who loses money but I won't be the one who owes them an apology. Equally, if Inanaco is right and SCLP hits £8 a share, I'll be the first to congratulate him. Finally to answer your question, no I am not associated with any fund at all whether they have a position in Scancell or not, nor am I connected to any commercial entity with a position in SCLP. |
Posted at 13/6/2025 05:53 by inanaco Marcus is not comparing thou is he Moljen its youBut at the end of the day the Stock market does not have a clue because if the stock market was valuing correctly there would be NO buyers premium even so despite all the numbers coming out of Scancell regarding the market size for the vaccines, and we know the cost of trials etc, there is no correlation between risk wrung out of SCIB1 and the stock price. All one can do is consider the Data and buy more on the basis that at some point a Premium Deal will appear As for BioNtech buying up Curevac, really is of no concern to us indeed we have yet to see Clinical evidence that BionTech can even compete with us in the cancer arena We all ready know that Big Pharma follow trends .... well Lets see how they can compete with Scancell because as it stands we WILL become "Standard of Care" There is absolutely no point in posting on the science it is not being absorbed, now it maybe because i am Happy with the data it creates confidence or those that follow Bermuda prefer to be out before news or hold a small holding. That is how it is its all about the confidence to be a buyer, and to see the share price as a Treat rather than a anchor after all Scancell does not need to raise at this level, and the way they keep expanding suggests the opposite to Doomsters forecasts and any accountant will tell you ... Its all about the number you hold at the time of the Premium RNS mot the number you don't because 10p is derisory but potential sales of $20billion a year is NOT I have already shown that the Self Antigens in the vaccine are present in Pre Cancer lesions in which case the T cells "will" kill Them, the trials are just to prove it . |
Posted at 10/6/2025 10:40 by markingtime The "bid premium" issue is a function of the initial base price. Arguably, the current price "should be" in the 30-35p range, in which case a 96% premium for control (ie c.65p or so) would be about right at present.But, even though the market price is currently much lower, the "ask" of Redmile and Vulpes will not change! And if that means a premium of 500%+, then so be it. They know the value of the IP and, since they regarded 17p or thereabouts as "derisory" a few years back, you can be 100% certain that they won't agree to a sale anywhere near the current share price, irrespective of the bid premium being suggested. |
Posted at 06/6/2025 07:55 by sci102 I am going to take a wild guess outside my field, which can easily result in a humiliating miscalculation, but given I haven't actually seen any credible scenario in these forums, here it is:A large shareholder that is also an institution (big fund, broker etc) and therefore has the permission to trade outside the market has found some idiots, ahem, investors to offload some shares to. It could also be from one client of an instituion to another client of the same, so the selling party benefits by offloading largish volumes without dropping the share price after the first transaction, while the fools, *cough* I mean the buyers, benefit by buying relatively large volumes without worrying that the share price spikes after the first transaction. No idea if that is actually happening, but in my head it is a likely scenario. |
Posted at 29/4/2025 14:14 by ruckrover Quite frankly, I'm beginning to realise that the TD estimates have rather limited value. The figures are based on certain assumptions made many years ago. Probability of success is unchanged despite the passage of time and further data being released.The investor presentation on 24th April was very interesting, not to mention encouraging. Two really important things mentioned by Phil D'Hullier: 1) The potential market size for SCIB1/iSCIB1+ - up to $19.5B if use extended beyond the unresectable group. 2) Phil states that risk has been "wrung out". He says "we know we've got good efficacy, we know we've got good safety. So TD are still using a market size for SCIB1 of $4.8 and a probability of success of 5-10%. All this results in a TD estimate of 32p per share. No mention of dilution at all. So personally, I'm going to ditch the TD model as far as share price estimates go and develop my own. As far as I can see, the share price potential can be calculated using only the following variables: Annual market value Royalty % Mcap to turnover ratio Number of shares in issue If anyone thinks there is any other parameters that need to be plugged in let me know. |
Posted at 20/4/2025 07:46 by inanaco I suppose he could use Rucks (data Scientist) statistical analysis"any patient failing is an anomaly" and the data should be discarded I see he is back doing an Analysis of the share price .. and he has assumed dilution of 100% to cover cost of Reg trial .... but seems to have ignored the approval and potential income generated per year by 2031 of $9 billion per year with 2 billion shares in issue the income stream would be over $4 a share so why would the share price be £5 ? even simple property capital values are 10 x rental earnings I understand why you are having a moan Bermuda .. but surely letting Ruck roam the plains is far more dangerous with Red Flags |
Posted at 15/4/2025 10:04 by chilltime The point of the posts is the supply has stifled the share price sending it backwards.But when you gather the info it shows what is recorded as with a holder could be out by 30m in the details above. Even if I split it in 2 for double recording it's 15m. And the same broker that has been seen before did far more than the 2.5m reported yesterday in a trade and it seemed they picked zero up from the market as they were not on the bid, but then randomly appeared on the offer for most of the day. When they left late in the day, that's why the share price went up again as he market makers behind them had no stock to meet the demand. So personally for now I think Calculus have somewhere between 15m and 35m less than we know from existing official records. And when it's gone, it's gone. |
Posted at 15/4/2025 09:40 by chilltime Jan trade data.How late reports often work with a supply or buy order. Broker gets 5m mill request either way and they work the order, and report it once complete, which depending on volumes can be hours, a week or weeks. Hence you get the random large number reports which don't move the share price, some examples for Scancell are below. We know the trend 500k here or the supply 350k there after hours etc. then the occasional 2 mill 6 mill which are just reporting post having fed or bought them for the market over a period. So January Up to the 14th about 2 mill in Total came from the 500k, 350k etc game. Jan 15th 6.239 mill, 2 mill, 1.5m, 400k, with marginal move in the share price. In other words late reports probably after weeks as the volumes could not deal with that. Ignoring the 400k that's just shy of 10m shares reported that day. 17th 1m 20th 1.69m 21st 1.75m & 875k 22nd 625k & 500k 24th 1m $ 1.5m 3th 1.2m 12th Feb 3 x 250k 14th 385k Quiet as it dropped into the 8p range then 25th March 1.5m But go back to 30th Dec and there's a 6.2m trade. |
Posted at 15/4/2025 08:51 by 888icb A look back to last July may give us an idea where the share price is about to go. This RNS was released on 24th July 2024:“ Scancell Provides Update from iSCIB1+ Clinical Advisory Meeting to Strengthen Plans for Phase 2/3 Registration Clinical Trial A panel of international key opinion leaders in the treatment of Melanoma convened in Chicago to offer strategic guidance in the design of Scancell's Phase 2/3 seamless adaptive registration study. The SCIB1 stage 1 clinical data poster was very well received at ASCO. Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that a group of leading medical oncologists in the field of melanoma treatment reviewed and strengthened Scancell's plan for a Phase 2/3 registration study following completion of the ongoing SCOPE study. Scancell's plans to conduct an adaptive randomised controlled Phase 2/3 SCOPE-2 trial is supported by a panel of experts. The study is expected to have an early interim analysis of Overall Response Rate (ORR) based on a blinded independent centralised review of CT/MRI scans before advancing to the Phase 3 component where the primary endpoint of progression-free survival will be analysed at a predetermined landmark.” At the end of that RNS Lindy made this historic comment: “ Prof Lindy Durrant, Chief Executive Officer, Scancell said: "We are very grateful to the esteemed panel for their interest in our SCOPE results and their input into our further clinical study. The panel felt that the data was compelling enough to proceed to the Phase 2/3 randomised registration study upon the completion of the SCOPE study. We were also overwhelmed by the interest in the poster, which is the most significant response I have seen in my career." The share price rose quickly from 11p to 19p. It seems to me that yesterday’s news validates the earlier RNS and SCLP is clearly in a better place now and the share price should move quickly 20p+ |
Posted at 14/4/2025 14:53 by chilltime The second part, discussed a few times.The Scancell delays have created a perfect storm. Big names vying for the Melanoma cancer space with patents expiring, we don’t have to wonder if they are interested. One BMS therapy hit it’s patent cliff but they combined it with another which upped the standard of care dragging it beyond other therapies to 50% ORR. Melanoma stage 3/4 meant months to live about 10 years ago. 35% ORR then 50% came in. Others spy upping a single anti PDI vaccine combo to match 50% but less toxic to grab a market share. Then add in the suspected mono treatment post resected. We were talking $1.5b market but Iscib trebles that potential now earlier line treatment potential is quoted as $9b. Scib/Iscib has the potential in these combos to take the legs from under trials in progress that are seeking to match BMS. News on those trials triggers across this year and will likely coincide with no overhang and 100’s of more investors. EG Knowledge of Scancell I checked toplists, and some skin cosmetic company (never heard of them) tops the posts. I’m not going to look at them, and a host of other active BB shares I don’t know or care to look at. What I do know is one Friday I was about to invest here, got distracted, weekend paper article, no supply and the share price went north fast, and wouldn’t play ball retracing. That’s what no supply PI interest does and it was before all this impressive early data. So to me once any overhang is done, the share price will move up fast. Trying to gamble on when that may happen is pure lucky dip. News this year, 27 hit triggers the first scib news, just weeks away in my opinion. The full 43 read out mid year as they say. Iscib+ post 25 week data to come, and Modi on various fronts. Today, the prime minister tweeted about Scancell, you are on Angle, can you imagine that on Angle or Avacta, volumes would be crazy and no overhang. As Dom said it should be 30p on that but we have had for some time a spoilsport supply, that has no interest in potential multiples just boring 🥱 sell perhaps due to investors exiting their funds to invest in the new wave of non existent whisky casks and a slant on timeshare, fractional ownership through a growing band of fraudulent companies/people. So just a wait until the rocket ignites is my opinion. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
